- Home
- PAVM vs ONCO Comparison
PAVM vs ONCO Comparison
Compare PAVM & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- ONCO
- Stock Information
- Founded
- PAVM 2014
- ONCO 2018
- Country
- PAVM United States
- ONCO United States
- Employees
- PAVM N/A
- ONCO N/A
- Industry
- PAVM Medical/Dental Instruments
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- ONCO Health Care
- Exchange
- PAVM Nasdaq
- ONCO Nasdaq
- Market Cap
- PAVM 10.4M
- ONCO 4.7M
- IPO Year
- PAVM 2016
- ONCO 2022
- Fundamental
- Price
- PAVM $0.51
- ONCO $3.38
- Analyst Decision
- PAVM Strong Buy
- ONCO
- Analyst Count
- PAVM 1
- ONCO 0
- Target Price
- PAVM $20.00
- ONCO N/A
- AVG Volume (30 Days)
- PAVM 453.7K
- ONCO 285.8K
- Earning Date
- PAVM 11-12-2025
- ONCO 08-14-2025
- Dividend Yield
- PAVM N/A
- ONCO N/A
- EPS Growth
- PAVM N/A
- ONCO N/A
- EPS
- PAVM 0.83
- ONCO N/A
- Revenue
- PAVM $1,020,000.00
- ONCO $1,326,959.00
- Revenue This Year
- PAVM N/A
- ONCO N/A
- Revenue Next Year
- PAVM $234.47
- ONCO N/A
- P/E Ratio
- PAVM $0.61
- ONCO N/A
- Revenue Growth
- PAVM N/A
- ONCO N/A
- 52 Week Low
- PAVM $0.30
- ONCO $2.45
- 52 Week High
- PAVM $1.25
- ONCO $552.50
- Technical
- Relative Strength Index (RSI)
- PAVM 58.39
- ONCO 51.12
- Support Level
- PAVM $0.45
- ONCO $3.51
- Resistance Level
- PAVM $0.60
- ONCO $4.17
- Average True Range (ATR)
- PAVM 0.05
- ONCO 0.28
- MACD
- PAVM 0.01
- ONCO 0.00
- Stochastic Oscillator
- PAVM 46.17
- ONCO 35.51
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.